CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score 7.09: safe zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.81%
Annual Rate
CNY 0.22Paid annual
Payout Ratio
21.9%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.37BCNY352.22M · vs all stocks (USD)
Trailing P/E
63.05xvs Biotechnology peers
Revenue (TTM)
412.51MCNY61.27M · vs all stocks (USD)
Profit Margin
9.11%vs Biotechnology peers
Beta
0.3670xvs all stocks
52-Week Change
-26.77%vs all stocks
Market Capitalization
2.37BCNY352.22M · vs all stocks (USD)
Enterprise Value
1.23BCNY182.43M · vs all stocks (USD)
Trailing P/E
63.05xvs Biotechnology peers
Price to Sales (TTM)
5.88xvs Biotechnology peers
Price to Book (MRQ)
1.26xvs Biotechnology peers
Enterprise to Revenue
2.98xvs Biotechnology peers
Enterprise to EBITDA
37.04xvs Biotechnology peers
Gross Margin
18.56%vs Biotechnology peers
Profit Margin
9.11%vs Biotechnology peers
Operating Margin
-4.94%vs Biotechnology peers
Return on Assets (TTM)
-0.40%vs Biotechnology peers
Return on Equity (TTM)
1.99%vs Biotechnology peers
Revenue (TTM)
412.51MCNY61.27M · vs all stocks (USD)
Revenue per Share (TTM)
4.58CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-17.90%vs Biotechnology peers
Gross Profit (TTM)
71.59MCNY10.63M · vs all stocks (USD)
EBITDA (TTM)
72.66MCNY10.79M · vs all stocks (USD)
Net Income (TTM)
37.59MCNY5.58M · vs all stocks (USD)
Operating Cash Flow (TTM)
36.75MCNY5.46M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-115.07MCNY-17.09M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2200CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.81%vs all stocks
Payout Ratio
21.92%vs Biotechnology peers
Revenue
432.73MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
360.52MCNYFY2025 · Dec 31, 2025Gross Profit
72.21MCNYFY2025 · Dec 31, 2025Operating Income
-8.10MCNY-1.20M · vs all stocks (USD)
Pre-tax Income
74.85MCNYFY2025 · Dec 31, 2025Income Tax Expense
10.55MCNYFY2025 · Dec 31, 2025Net Income
64.29MCNYFY2025 · Dec 31, 2025EBIT
74.91MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
72.66MCNYFY2025 · Dec 31, 2025Research & Development
35.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
16.27MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
63.81KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
90.56MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
90.56MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
64.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
102.97MCNYFY2025 · Dec 31, 2025Free Cash Flow
-42.78MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
361.68MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
64.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
3.44MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
29.82MCNYFY2025 · Dec 31, 2025Capital Expenditures
-145.75MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.55BCNYFY2025 · Dec 31, 2025Sale of Investments
2.86BCNYFY2025 · Dec 31, 2025Other Investing Activity
-141.60KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
161.82MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.26MCNYFY2025 · Dec 31, 2025Other Financing Charges
-79.13MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-87.39MCNYFY2025 · Dec 31, 2025Shares Outstanding
91.67MSharesUpdated Aug 20, 2026Float Shares
30.74MSharesUpdated Aug 20, 2026% Held by Insiders
64.86%vs all stocks
% Held by Institutions
1.28%vs all stocks
Total Cash (MRQ)
1.16BCNY172.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.14CNYUpdated Aug 20, 2026Total Debt (MRQ)
836.43KCNY124.23K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0004xvs Biotechnology peers
Current Ratio (MRQ)
10.36xvs Biotechnology peers
Book Value per Share (MRQ)
21.02CNYUpdated Aug 20, 2026Total Assets
2.12BCNY314.85M · vs all stocks (USD)
Total Current Assets
1.51BCNYFY2025 · Dec 31, 2025Total Liabilities
255.33MCNYFY2025 · Dec 31, 2025Total Non-current Assets
610.09MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
57.32MCNYFY2025 · Dec 31, 2025Total Current Liabilities
198.01MCNYFY2025 · Dec 31, 2025Cash
327.47MCNYFY2025 · Dec 31, 2025Cash Equivalents
34.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
361.68MCNYFY2025 · Dec 31, 2025Other Short-term Investments
899.07MCNYFY2025 · Dec 31, 2025Accounts Receivable
59.33MCNYFY2025 · Dec 31, 2025Inventory
132.45MCNYFY2025 · Dec 31, 2025Accounts Payable
173.27MCNYFY2025 · Dec 31, 2025Short-term Debt
706.57KCNYFY2025 · Dec 31, 2025Other Current Liabilities
109.24KCNYFY2025 · Dec 31, 2025Long-term Debt
303.57KCNYFY2025 · Dec 31, 2025Common Stock (Book)
91.67MCNYFY2025 · Dec 31, 2025Retained Earnings
681.00MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.86BCNY276.93M · vs all stocks (USD)
Treasury Stock
98.51MCNYFY2025 · Dec 31, 202552-Week Low
21.78CNYUpdated Aug 20, 202652-Week High
38.31CNYUpdated Aug 20, 202652-Week Change
-26.77%vs all stocks
Beta
0.3670xvs all stocks
50-Day MA
24.40CNYUpdated Aug 20, 2026200-Day MA
30.53CNYUpdated Aug 20, 2026Avg 10-Day Volume
1.69MSharesUpdated Aug 20, 2026Avg 30-Day Volume
1.70MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.4200CNYUpdated Aug 20, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Altman Z-Score 7.09: safe zoneNotable
Altman Z-Score: 7.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhubo Design Co. Ltd.
5 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityCash Backing With OCF Coverage And Cash Near Total DebtPrice Below Mean With Profitability And EquityClose Below 40W SMA With ProfitabilityDebt Falling While Share Count Rises
Oriental Watch Holdings Limited
4 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityCash Backing With OCF Coverage And Cash Near Total DebtPrice Below Mean With Profitability And EquityClose Below 40W SMA With Profitability
Assure Tech Hangzhou Co., Ltd.
4 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityPrice Below Mean With Profitability And EquityClose Below 40W SMA With ProfitabilityDebt Falling While Share Count Rises